March 21, 2017

Biogazelle presents ‘RNA capture sequencing’ at Revolutionizing next-generation sequencing in Antwerp

Biogazelle’s CSO prof. Jo Vandesompele presented Biogazelle’s strategy and expertise to deploy RNA in liquid biopsies to further diagnostic applications and drug development at “Revolutionizing next-generation sequencing” (Antwerp, Belgium).
March 6, 2017

Biogazelle offers mRNA sequencing on plasma – interview with CSO prof. Jo Vandesompele

Biogazelle was one of the first to offer microRNA expression profiling of challenging samples such as RNA from body fluids or archived tissues. Further building on its longstanding track record and internationally recognized expertise in RNA gene expression analysis, Biogazelle subsequently extended its portfolio with mRNA and total RNA sequencing on FFPE tissue. Today, Biogazelle closes the gap with a new and unique offer, namely the use of massively parallel sequencing to quantify and characterize mRNA in plasma. Biogazelle’s CSO prof. Jo Vandesompele is very excited about this new application Biogazelle offers to its customers today. In this interview, he elaborates on the unique nature and the value of this product.
September 14, 2016

Biogazelle presents ‘Liquid biopsy RNA biomarkers’ at NLS days in Stockholm

Belgium — September 14, 2016 — Biogazelle’s CEO dr Jan Hellemans will present Biogazelle’s strategy and expertise to deploy RNA in liquid biopsies to further diagnostic applications and drug development at the “Nordic Life Science days 2016” (Stockholm, Sweden). A PDF version of the presentation is available from the Knowledge center on Biogazelle’s website.

March 24, 2016

Nature publishes study on melanoma addiction to the long non-coding RNA SAMMSON, providing solid proof-of-concept for Biogazelle’s lncRNA targeting anti-cancer platform

The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other cancer types. Using antisense mediated RNA targeting therapy, Leucci et al. selectively kill melanoma cells in vitro and in vivo xenograft mouse models.